InsidersTradesSigma
Track the Legend Biotech Corp share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €4bn. The latest transaction was disclosed on 18 August 2026 (Attribution). Among the most active insiders: Huang Ying. Every trade is openly available.
Analysts rate Legend Biotech Corp Buy (bullish), based on 15 analysts. Average price target: US$49.25.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Legend Biotech Corp is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. It is listed on NASDAQ under the ticker symbol LEGN.